Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Lawsuit - RCKTNEW YORK - July 8, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming DeadlineNEW YORK, July 07, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Investors in Rocket Pharmaceuticals, Inc. Should Contact Levi & Korsinsky Before August 11, 2025 to Discuss Your Rights - RCKTNEW YORK - July 7, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTNEW YORK, July 06, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Shareholders That Lost Money on Rocket Pharmaceuticals, Inc. (RCKT) Should Contact Levi & Korsinsky About Pending Class Action - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders That Lost Money on Rocket Pharmaceuticals, Inc. (RCKT) Should Contact Levi & Korsinsky About Pending Class Action - RCKTNEW YORK - July 3, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
Shareholders That Lost Money on Rocket Pharmaceuticals, Inc. (RCKT) Should Contact Levi & Korsinsky About Pending Class Action - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Shareholders That Lost Money on Rocket Pharmaceuticals, Inc. (RCKT) Should Contact Levi & Korsinsky About Pending Class Action - RCKTNEW YORK - July 2, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket PharmaceuticalsFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit - RCKTNEW YORK - July 1, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTNEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors With Losses on Their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit And Upcoming Deadlines - RCKTNEW YORK CITY, NY / ACCESS Newswire / June 30, 2025 / Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ:RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
ROCKET PHARMACEUTICALS, INC. (NASDAQ: RCKT) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Rocket Pharmaceuticals, Inc. Investors of Upcoming DeadlineNEW YORK, June 30, 2025 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT) investors of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit - RCKTSearch for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of August 11, 2025 in Rocket Pharmaceuticals, Inc. Lawsuit - RCKTNEW YORK - June 30, 2025 ( NEWMEDIAWIRE ) - Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (
NASDAQ: RCKT) of a class action securities lawsuit.
Rocket Pharmaceuticals Announces FDA IND Clearance of RP-A701 for the Treatment of BAG3-associated Dilated Cardiomyopathy
Rocket Pharmaceuticals, Inc. (
NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare disorders with high unmet need, today announced that it has received clearance from the U.S. Food and Drug Administration (FDA) for the Company’s Investigational New Drug (IND) application for RP-A701, an AAVrh.74-based gene therapy candidate for the treatment of BAG3-associated Dilated Cardiomyopathy (BAG3-DCM), a severe form of heart failure characterized by progressive ventricular enlargement and impaired systolic function.
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Rocket Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadlines - RCKTNEW YORK, June 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Rocket Pharmaceuticals, Inc. (“Rocket” or the “Company”) (
NASDAQ: RCKT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
RCKT Investors Have the Opportunity to Lead the Rocket Pharmaceuticals Securities Fraud Lawsuit with Faruqi & Faruqi, LLPFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Rocket Pharmaceuticals To Contact Him Directly To Discuss Their Options
